Ensartinib for advanced tumors with ALK or MET changes
Treatments studied
Part of Cancer clinical trials.
This trial tests a targeted therapy pill called ensartinib for people with advanced solid tumors (other than lung cancer) that have an ALK or MET gene change. The drug works by blocking signals that help these cancers grow, and the study aims to see how well it works and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced or have spread, and it cannot be a primary lung cancer (cancer that started in the lungs).
- Your tumor must have an ALK or MET gene change (found through a biopsy or blood test).
- Standard treatment options must not be available to you, or you cannot tolerate them, or you decided against them after a team discussion.
- You must have adequate liver, kidney, and bone marrow function.
- You must be able to take oral medication and follow the study schedule.
- You must not be pregnant, and you must not have an active infection or a history of lung inflammation (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to ensartinib, an oral medication that targets a specific genetic change in non-small cell lung cancer (NSCLC). It is for people who cannot join other clinical trials for ensartinib and may help control the cancer.
This trial tests a pill called ensartinib, given before surgery to people with ALK-positive lung cancer. The goal is to see if it helps shrink the tumor and improve the chance of successful surgery.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
This trial tests whether taking ensartinib after surgery can lower the chance of lung cancer coming back in people whose tumors have a specific genetic change called ALK. The study uses a blood test called MRD to guide treatment.
This trial tests a pill called ensartinib after you finish chemotherapy and radiation for stage III ALK-positive lung cancer. It may help keep the cancer from coming back.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.